ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer

NCT00959959 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: TOK-001
DRUG: TOK-001
DRUG: TOK-001
DRUG: TOK-001
DRUG: TOK-001
DRUG: TOK-001
DRUG: TOK-001
DRUG: TOK-001

Sponsor

LTN PHARMACEUTICALS, INC.